Von Willebrand factor's clearance

被引:0
作者
Denis, Cecile V. [1 ]
Lenting, Peter J. [2 ]
机构
[1] INSERM, Unite 143, 80 Rue General Leclerc, F-94276 Le Kremlin Bicetre, France
[2] Univ Med Ctr Utrecht, Dept Haematol, Lab Thrombosis & Haemostasis, Utrecht, Netherlands
来源
HEMATOLOGIE | 2006年 / 12卷 / 01期
关键词
von Willebrand factor; von Willebrand disease; clearance; gene modifier; mutations; in vivo models;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Von Willebrand factor (FVW) is a multimeric plasma glycoprotein that plays two major roles in hemostasis: it promotes platelet adhesion to the subendothelium in case of vascular injury and it carries and protects coagulation FVIII in the circulation. FVW plasma concentration requires tight regulation since a reduced level may result in a bleeding tendency whereas an elevated concentration is associated with an increased thrombotic risk. Plasma levels represent a balance between biosynthetic and catabolic pathways. With regard to FVW, its biosynthetic pathways has been well studied in the past while relatively little is known concerning its clearance mechanism. However, recent data point to abnormal clearance as being a potential cause for von Willebrand disease, the most common inherited bleeding disorder in humans. Defective clearance may originate from a variety of reasons: mutations in the FVW gene, effect of a gene modifier or increase functionality of the FVW clearance mechanism. In this review, we will give an update of the present knowledge on how FVW is cleared from the circulation and how this process is regulated.
引用
收藏
页码:34 / 43
页数:10
相关论文
共 48 条
[1]  
Allen S, 2000, BLOOD, V96, P560
[2]   Quantitative analysis of von Willebrand factor propeptide release in vivo: Effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans [J].
Borchiellini, A ;
Fijnvandraat, K ;
tenCate, JW ;
Pajkrt, D ;
vanDeventer, SJH ;
Pasterkamp, G ;
MeijerHuizinga, F ;
ZwartHuinink, L ;
Voorberg, J ;
vanMourik, JA .
BLOOD, 1996, 88 (08) :2951-2958
[3]  
Bowen DJ, 2003, THROMB HAEMOSTASIS, V90, P961
[4]   An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13 [J].
Bowen, DJ .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (01) :33-40
[5]   Increased clearance of von Willebrand factor antigen post-DDAVP in type 1 von Willebrand disease: is it a potential pathogenic process? [J].
Brown, SA ;
Eldridge, A ;
Collins, PW ;
Bowen, DJ .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (08) :1714-1717
[6]   Significant linkage and non-linkage of type 1 von Willebrand disease to the von Willebrand factor gene [J].
Casaña, P ;
Martínez, F ;
Haya, S ;
Espinós, C ;
Aznar, JA .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (03) :692-700
[7]   Reduced von Willebrand factor survival in type Vicenza von Willebrand disease [J].
Casonato, A ;
Pontara, E ;
Sartorello, F ;
Cattini, MG ;
Sartori, MT ;
Padrini, R ;
Girolami, A .
BLOOD, 2002, 99 (01) :180-184
[8]   Sialyltransferase ST3Gal-IV operates as a dominant modifier of hemostasis by concealing asialoglycoprotein receptor ligands [J].
Ellies, LG ;
Ditto, D ;
Levy, GG ;
Wahrenbrock, M ;
Ginsburg, D ;
Varki, A ;
Le, DT ;
Marth, JD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (15) :10042-10047
[9]   INTERINDIVIDUAL VARIATION IN HALF-LIFE OF INFUSED RECOMBINANT FACTOR-VIII IS RELATED TO PRE-INFUSION VON-WILLEBRAND-FACTOR ANTIGEN LEVELS [J].
FIJNVANDRAAT, K ;
PETERS, M ;
TENCATE, JW .
BRITISH JOURNAL OF HAEMATOLOGY, 1995, 91 (02) :474-476
[10]  
Gavazova S, 2003, J THROMB HAEMOST S, V1